Cloud-Clone launches DHVD3 ELISA kit for trace-level vitamin D research

Cloud-Clone says its new 1,25-dihydroxyvitamin D3 ELISA kit is designed to solve sensitivity, cross-reactivity and sample-stability problems that have made DHVD3 hard to measure in biomedical research. The kit targets bone, immune, metabolic, renal and oncology studies where accurate DHVD3 data can shape mechanistic and drug-development work.

Why it matters: - 1,25-dihydroxyvitamin D3, or DHVD3, is the biologically active form of vitamin D and is used in research on bone metabolism, immunity, endocrine balance, kidney disease, cardiovascular science and cancer. - Accurate DHVD3 measurement is difficult because the hormone is present at trace levels, degrades quickly and is easily confounded by similar vitamin D metabolites and binding proteins. - Cloud-Clone’s new ELISA kit is aimed at making DHVD3 testing more reliable for basic research, animal studies and drug screening.

What happened: - Cloud-Clone Corp. introduced the 1,25-Dihydroxyvitamin D3 (DHVD3) ELISA Kit, Cat. No. CEA467Ge. - The product is positioned for multi-disciplinary biomedical research and is designed to quantify DHVD3 in human, rat, mouse and rabbit samples. - The company also published background material explaining DHVD3 biology, assay challenges and use cases across bone, immune, metabolic, renal, oncology and cardiovascular research.

The details: - DHVD3 is produced after vitamin D3 is converted in the liver to 25-hydroxyvitamin D3 and then in the kidney to 1,25-dihydroxyvitamin D3. - DHVD3 acts through vitamin D receptors found in bone, intestinal epithelium, kidney, immune cells, pancreatic islet cells and vascular endothelium. - The release says DHVD3 helps regulate calcium and phosphorus balance, parathyroid hormone secretion, bone mineralization and bone remodeling. - It also describes DHVD3 as relevant to immune modulation, glucose and lipid metabolism, renal protection, endothelial integrity and cell differentiation. - The assay uses custom antibodies designed to target the active di-hydroxylated structure of DHVD3. - Cloud-Clone says the antibodies show negligible cross-reactivity with 25-hydroxyvitamin D3, vitamin D2 and other steroid-related analogues. - The kit includes sample dilution and incubation buffers intended to reduce degradation from light exposure and temperature changes. - The assay is built to detect ultra-low analyte levels and capture small shifts seen in early disease or mild intervention models. - The kit supports serum, plasma, bone homogenate, kidney homogenate and cell culture supernatant. - The workflow does not require extraction, derivatization or purification, and complete testing finishes within three hours, according to the company. - Cloud-Clone says the kit uses a detachable 96-well plate format and ready-to-use reagents.

Between the lines: - The release frames DHVD3 as more than a vitamin D marker and positions it as a cross-disciplinary biomarker for mechanistic and translational studies. - The company is also contrasting ELISA with LC-MS/MS, radioimmunoassay and chemiluminescent immunoassay to argue that researchers need a lower-cost, higher-throughput option for routine work. - The strongest pitch is not novelty in DHVD3 biology. It is improved assay performance in hard-to-handle research samples.

What's next: - Cloud-Clone says the kit is intended for osteoporosis, rickets, osteomalacia, inflammation, autoimmune disease, diabetes, obesity, chronic kidney disease, fibrosis, tumor biology and compound screening studies. - The company says additional product specifications and technical inquiries are available through its official communication channels. - Cloud-Clone also says it will keep developing assay solutions for hormones, metabolic molecules and inflammatory biomarkers.

The bottom line: - Cloud-Clone is betting that better DHVD3 measurement will help researchers get cleaner data in fields where vitamin D signaling matters but standard assays have struggled.